Live Updates: COVID-19 Cases
  • World 30,737,361
    Confirmed: 30,737,361
    Active: 7,406,980
    Recovered: 22,373,138
    Death: 957,243
  • USA 6,928,304
    Confirmed: 6,928,304
    Active: 2,532,342
    Recovered: 4,192,774
    Death: 203,188
  • India 5,312,537
    Confirmed: 5,312,537
    Active: 1,018,456
    Recovered: 4,208,431
    Death: 85,650
  • Brazil 4,497,434
    Confirmed: 4,497,434
    Active: 572,438
    Recovered: 3,789,139
    Death: 135,857
  • Russia 1,097,251
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 756,412
    Confirmed: 756,412
    Active: 124,334
    Recovered: 600,795
    Death: 31,283
  • Mexico 688,954
    Confirmed: 688,954
    Active: 123,959
    Recovered: 492,192
    Death: 72,803
  • Spain 659,334
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • South Africa 657,627
    South Africa
    Confirmed: 657,627
    Active: 54,926
    Recovered: 586,844
    Death: 15,857
  • Chile 442,827
    Confirmed: 442,827
    Active: 14,647
    Recovered: 415,981
    Death: 12,199
  • France 428,696
    Confirmed: 428,696
    Active: 305,873
    Recovered: 91,574
    Death: 31,249
  • Iran 419,043
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 385,936
    Confirmed: 385,936
    Active: 344,204
    Recovered: ?
    Death: 41,732
  • Bangladesh 347,372
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 305,031
    Confirmed: 305,031
    Active: 6,572
    Recovered: 292,044
    Death: 6,415
  • Turkey 299,810
    Confirmed: 299,810
    Active: 27,628
    Recovered: 264,805
    Death: 7,377
  • Italy 294,932
    Confirmed: 294,932
    Active: 42,457
    Recovered: 216,807
    Death: 35,668
  • Germany 271,244
    Confirmed: 271,244
    Active: 18,780
    Recovered: 243,000
    Death: 9,464
  • Canada 141,911
    Confirmed: 141,911
    Active: 8,983
    Recovered: 123,723
    Death: 9,205
  • Netherlands 91,934
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,269
    Confirmed: 85,269
    Active: 171
    Recovered: 80,464
    Death: 4,634
  • Australia 26,885
    Confirmed: 26,885
    Active: 2,079
    Recovered: 23,962
    Death: 844
  • S. Korea 22,893
    S. Korea
    Confirmed: 22,893
    Active: 2,545
    Recovered: 19,970
    Death: 378
  • New Zealand 1,811
    New Zealand
    Confirmed: 1,811
    Active: 67
    Recovered: 1,719
    Death: 25

Researchers developed Therepi, a new device to stop heart failure after heart attack

Author at TechGenyz Science
Therepi Device

In the last week, a new study was published in Nature Biomedical Engineering that describes a new device named Therepi, which can be used for stopping heart failure after an attack. The study details how it can restore cardiac function.

According to the researchers, Therepi device possesses a reservoir that gets attached directly to the damaged heart tissue. It has a refill line that connects the reservoir with a port on or under the patient’s skin, right where the therapies can be injected through.

If the patient already has some degree of heart failure, we can use the device to attenuate the progression – Ellen Roche, assistant professor at MIT’s Department of Mechanical Engineering and Institute for Medical Engineering and Science.

She is the co-first author of the study.

Two traditional methods to stop heart failure are insufficient as well as invasive. Therepi device offers the delivery of therapy to the patient’s heart via administering the process. It also ensures drug delivery as many times needed. Additionally, the reservoir of the device can be implanted on the human heart via surgical processes only.

Therepi Drug DeliveryThe study mentions that the reservoir holds the outstanding potential to deliver the drug to heart. It is made out of a gelatin-based polymer, being half-spherically shaped, and its flat bottom gets attached to the affected tissue.

This flat bottom has an adjustable semi-permeable membrane. It can be adjusted to pass drugs consisting of larger materials to the heart directly. In stem cell therapy, the reservoir acts as a cell factory, where the cells stay within it for producing paracrine factors that boost healing in the damaged tissue of the heart.

There was a rat model of Therepi that demonstrated its effectiveness to improve cardiac function after a heart attack. Multiple doses of cells were administered to a damaged heart for over four weeks.

After that, hemodynamic changes were analyzed via a pressure volume catheter, and functional changes over time was compared via echocardiography. Results observed were positive, as the hearts using Therepi had more cardiac functions than hearts receiving a single injection or no treatment.

The capabilities of Therepi device has further opened ways for cardiac and other diagnosis types. Not just that it provides for multiple doses to deliver, but it can as well be used for measuring exact required dosage for various conditions.

While focusing on how the device can mitigate heart disease effects on the body, researchers found out that it can be used for other body parts too. Design optimization and adjustment of materials for constructing the reservoir will lead the device to become useful for a broad range of diseases and health problems.

The researchers of the study are from Harvard University, MIT, Trinity College Dublin, Ireland’s Royal Challenge of Surgeons, AMBER Center, and the National University of Ireland Galway. Medical science may just have taken one step ahead with the introduction of their developed device Therepi!